Industry-first stem cell bank for immune suppression-free, therapeutic use Cosmeceuticals and other programs with near-term revenue potential Current cell culture business with product development, supply and revenue Human parthenogenic stem cells (hpSCs) International Stem Cell Corporation (ISCO) is the first company to perfect the natural phenomenon of parthenogenesis to create human stem cells (hpSCs) from oocytes for therapeutic use. These cells are as pluripotent as embryonic stem cells (ESCs), yet avoid the ethical issues associated with use or destruction of human embryos. Unlike induced pluripotent stem cells (iPSs), hpSCs do not involve manipulation of gene expression back to a less a differentiated stage, which may become a safety or regulatory obstacle in the future. Unlike both ESCs and iPSs, hpSCs can be created in a homozygous form such that each line will be an immune match for thousands or millions of patients.
Business units UniStemCell™ ISCO has established a cGMP facility with which to build the industry’s first universal stem cell bank (www.unistemcell.com). The first lines will have high-frequency haplotypes from the primary US population groups. The company will offer its intellectual property, process technology and business franchise to other companies for development and commercialization of similar universal stem cell banks for other ethnic groups such as Asians and Hispanics. The strategy is to enable academic and corporate researchers around the world to use hpSCs for development of therapeutic solutions knowing that sister matching most patients immunologically will become available. ISCO’s business model resembles “Intel Inside™”, providing a general cell therapy “engine” for a range of therapeutic applications rather than the therapy itself. In the medium term, revenue will be generated from universal stem cell bank franchises across populations and scientists accessing these lines. This provides a “multiple-shots-on-goal” strategy where ISCO’s hpSC lines will be tested and developed by others across a range of potential applications and, longer-term, will provide the company with royalty from sales of each successful, hpSC-derived cellular therapeutic. ®
Lifeline Cell Technology Lifeline (www.lifelinecelltech.com) is an ISCO subsidiary that develops, manufactures and commercializes high-quality cells, media and reagents for the research market place. The subsidiary produces over 70 different products and offers client-specific solutions as well. ISCO has created the first homozygous hpSC line with a common haplotype. This and other lines have been differentiated into cells with characteristics of the eye (retinal pigment epithelium and cornea), liver and other tissues. Initially, the company focuses therapeutically on diseases where cell therapy has been proven clinically but there are limited sources of safe human cells.
Lifeline has a small US sales force and uses commercial partners globally for the Lifeline™ brand and in OEM arrangements, e.g. American Type Culture Collection (ATCC), Millipore and CellSystems Biotechnologie Vertrieb. A key Lifeline program involves development of human corneas to replace live animal eyes in drug, cosmetic and pesticide toxicology testing and to replace cadavers as a transplant source. Lifeline™ Skin Care Lifeline Skin Care (www.lifelineskincare.com) is an ISCO subsidiary that develops, manufactures and seeks to commercialize oil-free creams and gels that are designed specifically for growth and vitality of skin cells. These products use the accumulated experience of Lifeline’s DermaLife™ product line and apply liposomal nanotechnology and hpSC extracts.
US public listing
$30-60M market cap (52 wks)
Kenneth Aldrich, Chairman
2595 Jason Court
Oceanside, CA 92056, USA
Brian Lundstrom, President